Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Identifieur interne : 005402 ( Main/Exploration ); précédent : 005401; suivant : 005403Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Auteurs : Anna S. Lok [États-Unis] ; Huy Trinh [États-Unis] ; Giampiero Carosi [Italie] ; Ulus S. Akarca [Turquie] ; Adrian Gadano [Argentine] ; François Habersetzer [France] ; William Sievert [Australie] ; David Wong [Canada] ; Meghan Lovegren [États-Unis] ; David Cohen [États-Unis] ; Cyril Llamoso [États-Unis]Source :
- Gastroenterology [ 1528-0012 ] ; 2012.
Descripteurs français
- KwdFr :
- ADN viral (sang), Acides phosphoreux, Adulte, Adénine (analogues et dérivés), Adénine (effets indésirables), Adénine (usage thérapeutique), Alanine transaminase (sang), Antigènes e du virus de l'hépatite virale B (sang), Antiviraux (effets indésirables), Antiviraux (usage thérapeutique), Association de médicaments, Charge virale, Facteurs temps, Guanine (analogues et dérivés), Guanine (effets indésirables), Guanine (usage thérapeutique), Humains, Hépatite B chronique (diagnostic), Hépatite B chronique (traitement médicamenteux), Marqueurs biologiques (sang), Modèles linéaires, Phosphonates (effets indésirables), Phosphonates (usage thérapeutique), Résistance virale aux médicaments, Résultat thérapeutique, Virus de l'hépatite B (), Virus de l'hépatite B (croissance et développement), Virus de l'hépatite B (génétique), Virus de l'hépatite B (immunologie).
- MESH :
- analogues et dérivés : Adénine, Guanine.
- croissance et développement : Virus de l'hépatite B.
- diagnostic : Hépatite B chronique.
- effets indésirables : Adénine, Antiviraux, Guanine, Phosphonates.
- génétique : Virus de l'hépatite B.
- immunologie : Virus de l'hépatite B.
- sang : ADN viral, Alanine transaminase, Antigènes e du virus de l'hépatite virale B, Marqueurs biologiques.
- traitement médicamenteux : Hépatite B chronique.
- usage thérapeutique : Adénine, Antiviraux, Guanine, Phosphonates.
- Acides phosphoreux, Adulte, Association de médicaments, Charge virale, Facteurs temps, Humains, Modèles linéaires, Résistance virale aux médicaments, Résultat thérapeutique, Virus de l'hépatite B.
English descriptors
- KwdEn :
- Adenine (adverse effects), Adenine (analogs & derivatives), Adenine (therapeutic use), Adult, Alanine Transaminase (blood), Antiviral Agents (adverse effects), Antiviral Agents (therapeutic use), Biomarkers (blood), DNA, Viral (blood), Drug Resistance, Viral, Drug Therapy, Combination, Guanine (adverse effects), Guanine (analogs & derivatives), Guanine (therapeutic use), Hepatitis B e Antigens (blood), Hepatitis B virus (drug effects), Hepatitis B virus (genetics), Hepatitis B virus (growth & development), Hepatitis B virus (immunology), Hepatitis B, Chronic (diagnosis), Hepatitis B, Chronic (drug therapy), Humans, Linear Models, Organophosphonates (adverse effects), Organophosphonates (therapeutic use), Phosphorous Acids, Time Factors, Treatment Outcome, Viral Load.
- MESH :
- chemical , adverse effects : Adenine, Antiviral Agents, Guanine, Organophosphonates.
- chemical , analogs & derivatives : Adenine, Guanine.
- chemical , blood : Alanine Transaminase, Biomarkers, DNA, Viral, Hepatitis B e Antigens.
- chemical , therapeutic use : Adenine, Antiviral Agents, Guanine, Organophosphonates.
- diagnosis : Hepatitis B, Chronic.
- drug effects : Hepatitis B virus.
- drug therapy : Hepatitis B, Chronic.
- genetics : Hepatitis B virus.
- growth & development : Hepatitis B virus.
- immunology : Hepatitis B virus.
- Adult, Drug Resistance, Viral, Drug Therapy, Combination, Humans, Linear Models, Phosphorous Acids, Time Factors, Treatment Outcome, Viral Load.
Abstract
Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB). We compared the efficacy and safety of ETV monotherapy with those of a combination of ETV and TDF.
DOI: 10.1053/j.gastro.2012.05.037
PubMed: 22643350
Affiliations:
- Argentine, Australie, Canada, France, Italie, Turquie, États-Unis
- Alsace (région administrative), Californie, Connecticut, Grand Est, Michigan, Victoria (État)
- Melbourne, Strasbourg
- Université de Strasbourg
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003B70
- to stream PubMed, to step Curation: 003A32
- to stream PubMed, to step Checkpoint: 003A32
- to stream Ncbi, to step Merge: 000E33
- to stream Ncbi, to step Curation: 000E33
- to stream Ncbi, to step Checkpoint: 000E33
- to stream Main, to step Merge: 005648
- to stream Main, to step Curation: 005402
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.</title><author><name sortKey="Lok, Anna S" sort="Lok, Anna S" uniqKey="Lok A" first="Anna S" last="Lok">Anna S. Lok</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan. Electronic address: aslok@umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Division of Gastroenterology, University of Michigan Health System, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Trinh, Huy" sort="Trinh, Huy" uniqKey="Trinh H" first="Huy" last="Trinh">Huy Trinh</name><affiliation wicri:level="2"><nlm:affiliation>Pacific Health Foundation, San Jose, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pacific Health Foundation, San Jose</wicri:cityArea></affiliation></author><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Infectious and Tropical Disease, University of Brescia, Brescia</wicri:regionArea><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="Akarca, Ulus S" sort="Akarca, Ulus S" uniqKey="Akarca U" first="Ulus S" last="Akarca">Ulus S. Akarca</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation></author><author><name sortKey="Gadano, Adrian" sort="Gadano, Adrian" uniqKey="Gadano A" first="Adrian" last="Gadano">Adrian Gadano</name><affiliation wicri:level="1"><nlm:affiliation>Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires</wicri:regionArea><wicri:noRegion>Ciudad de Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Habersetzer, Francois" sort="Habersetzer, Francois" uniqKey="Habersetzer F" first="François" last="Habersetzer">François Habersetzer</name><affiliation wicri:level="4"><nlm:affiliation>Service d'Hépato-gastroentérologie, Nouvel Hôpital Civil, INSERM Unité 748, Université de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hépato-gastroentérologie, Nouvel Hôpital Civil, INSERM Unité 748, Université de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, Monash University, Monash Medical Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Wong, David" sort="Wong, David" uniqKey="Wong D" first="David" last="Wong">David Wong</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lovegren, Meghan" sort="Lovegren, Meghan" uniqKey="Lovegren M" first="Meghan" last="Lovegren">Meghan Lovegren</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author><author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author><author><name sortKey="Llamoso, Cyril" sort="Llamoso, Cyril" uniqKey="Llamoso C" first="Cyril" last="Llamoso">Cyril Llamoso</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22643350</idno><idno type="pmid">22643350</idno><idno type="doi">10.1053/j.gastro.2012.05.037</idno><idno type="wicri:Area/PubMed/Corpus">003B70</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B70</idno><idno type="wicri:Area/PubMed/Curation">003A32</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A32</idno><idno type="wicri:Area/PubMed/Checkpoint">003A32</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A32</idno><idno type="wicri:Area/Ncbi/Merge">000E33</idno><idno type="wicri:Area/Ncbi/Curation">000E33</idno><idno type="wicri:Area/Ncbi/Checkpoint">000E33</idno><idno type="wicri:Area/Main/Merge">005648</idno><idno type="wicri:Area/Main/Curation">005402</idno><idno type="wicri:Area/Main/Exploration">005402</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.</title><author><name sortKey="Lok, Anna S" sort="Lok, Anna S" uniqKey="Lok A" first="Anna S" last="Lok">Anna S. Lok</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology, University of Michigan Health System, Ann Arbor, Michigan. Electronic address: aslok@umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Michigan</region></placeName><wicri:cityArea>Division of Gastroenterology, University of Michigan Health System, Ann Arbor</wicri:cityArea></affiliation></author><author><name sortKey="Trinh, Huy" sort="Trinh, Huy" uniqKey="Trinh H" first="Huy" last="Trinh">Huy Trinh</name><affiliation wicri:level="2"><nlm:affiliation>Pacific Health Foundation, San Jose, California.</nlm:affiliation><country>États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Pacific Health Foundation, San Jose</wicri:cityArea></affiliation></author><author><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Institute of Infectious and Tropical Disease, University of Brescia, Brescia</wicri:regionArea><wicri:noRegion>Brescia</wicri:noRegion></affiliation></author><author><name sortKey="Akarca, Ulus S" sort="Akarca, Ulus S" uniqKey="Akarca U" first="Ulus S" last="Akarca">Ulus S. Akarca</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir</wicri:regionArea><wicri:noRegion>Izmir</wicri:noRegion></affiliation></author><author><name sortKey="Gadano, Adrian" sort="Gadano, Adrian" uniqKey="Gadano A" first="Adrian" last="Gadano">Adrian Gadano</name><affiliation wicri:level="1"><nlm:affiliation>Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina.</nlm:affiliation><country xml:lang="fr">Argentine</country><wicri:regionArea>Sección Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires</wicri:regionArea><wicri:noRegion>Ciudad de Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Habersetzer, Francois" sort="Habersetzer, Francois" uniqKey="Habersetzer F" first="François" last="Habersetzer">François Habersetzer</name><affiliation wicri:level="4"><nlm:affiliation>Service d'Hépato-gastroentérologie, Nouvel Hôpital Civil, INSERM Unité 748, Université de Strasbourg, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'Hépato-gastroentérologie, Nouvel Hôpital Civil, INSERM Unité 748, Université de Strasbourg, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement><settlement type="city">Strasbourg</settlement></placeName><orgName type="university">Université de Strasbourg</orgName></affiliation></author><author><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name><affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Medicine, Monash University, Monash Medical Centre, Melbourne</wicri:regionArea><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Wong, David" sort="Wong, David" uniqKey="Wong D" first="David" last="Wong">David Wong</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Hospital, University Health Network, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Lovegren, Meghan" sort="Lovegren, Meghan" uniqKey="Lovegren M" first="Meghan" last="Lovegren">Meghan Lovegren</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author><author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author><author><name sortKey="Llamoso, Cyril" sort="Llamoso, Cyril" uniqKey="Llamoso C" first="Cyril" last="Llamoso">Cyril Llamoso</name><affiliation wicri:level="2"><nlm:affiliation>Research and Development, Bristol-Myers Squibb Company, Wallingford, Connecticut.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Connecticut</region></placeName><wicri:cityArea>Research and Development, Bristol-Myers Squibb Company, Wallingford</wicri:cityArea></affiliation></author></analytic><series><title level="j">Gastroenterology</title><idno type="eISSN">1528-0012</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenine (adverse effects)</term><term>Adenine (analogs & derivatives)</term><term>Adenine (therapeutic use)</term><term>Adult</term><term>Alanine Transaminase (blood)</term><term>Antiviral Agents (adverse effects)</term><term>Antiviral Agents (therapeutic use)</term><term>Biomarkers (blood)</term><term>DNA, Viral (blood)</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>Guanine (adverse effects)</term><term>Guanine (analogs & derivatives)</term><term>Guanine (therapeutic use)</term><term>Hepatitis B e Antigens (blood)</term><term>Hepatitis B virus (drug effects)</term><term>Hepatitis B virus (genetics)</term><term>Hepatitis B virus (growth & development)</term><term>Hepatitis B virus (immunology)</term><term>Hepatitis B, Chronic (diagnosis)</term><term>Hepatitis B, Chronic (drug therapy)</term><term>Humans</term><term>Linear Models</term><term>Organophosphonates (adverse effects)</term><term>Organophosphonates (therapeutic use)</term><term>Phosphorous Acids</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (sang)</term><term>Acides phosphoreux</term><term>Adulte</term><term>Adénine (analogues et dérivés)</term><term>Adénine (effets indésirables)</term><term>Adénine (usage thérapeutique)</term><term>Alanine transaminase (sang)</term><term>Antigènes e du virus de l'hépatite virale B (sang)</term><term>Antiviraux (effets indésirables)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Charge virale</term><term>Facteurs temps</term><term>Guanine (analogues et dérivés)</term><term>Guanine (effets indésirables)</term><term>Guanine (usage thérapeutique)</term><term>Humains</term><term>Hépatite B chronique (diagnostic)</term><term>Hépatite B chronique (traitement médicamenteux)</term><term>Marqueurs biologiques (sang)</term><term>Modèles linéaires</term><term>Phosphonates (effets indésirables)</term><term>Phosphonates (usage thérapeutique)</term><term>Résistance virale aux médicaments</term><term>Résultat thérapeutique</term><term>Virus de l'hépatite B ()</term><term>Virus de l'hépatite B (croissance et développement)</term><term>Virus de l'hépatite B (génétique)</term><term>Virus de l'hépatite B (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adenine</term><term>Antiviral Agents</term><term>Guanine</term><term>Organophosphonates</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenine</term><term>Guanine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Alanine Transaminase</term><term>Biomarkers</term><term>DNA, Viral</term><term>Hepatitis B e Antigens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenine</term><term>Antiviral Agents</term><term>Guanine</term><term>Organophosphonates</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Adénine</term><term>Guanine</term></keywords><keywords scheme="MESH" qualifier="croissance et développement" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hepatitis B, Chronic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Adénine</term><term>Antiviraux</term><term>Guanine</term><term>Phosphonates</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de l'hépatite B</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Hepatitis B virus</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>ADN viral</term><term>Alanine transaminase</term><term>Antigènes e du virus de l'hépatite virale B</term><term>Marqueurs biologiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hépatite B chronique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adénine</term><term>Antiviraux</term><term>Guanine</term><term>Phosphonates</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Resistance, Viral</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Linear Models</term><term>Phosphorous Acids</term><term>Time Factors</term><term>Treatment Outcome</term><term>Viral Load</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Acides phosphoreux</term><term>Adulte</term><term>Association de médicaments</term><term>Charge virale</term><term>Facteurs temps</term><term>Humains</term><term>Modèles linéaires</term><term>Résistance virale aux médicaments</term><term>Résultat thérapeutique</term><term>Virus de l'hépatite B</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are potent antiviral agents that might have additive or synergistic antiviral activity in treatment of patients with chronic hepatitis B (CHB). We compared the efficacy and safety of ETV monotherapy with those of a combination of ETV and TDF.</div></front></TEI><affiliations><list><country><li>Argentine</li><li>Australie</li><li>Canada</li><li>France</li><li>Italie</li><li>Turquie</li><li>États-Unis</li></country><region><li>Alsace (région administrative)</li><li>Californie</li><li>Connecticut</li><li>Grand Est</li><li>Michigan</li><li>Victoria (État)</li></region><settlement><li>Melbourne</li><li>Strasbourg</li></settlement><orgName><li>Université de Strasbourg</li></orgName></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Lok, Anna S" sort="Lok, Anna S" uniqKey="Lok A" first="Anna S" last="Lok">Anna S. Lok</name></region><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name><name sortKey="Llamoso, Cyril" sort="Llamoso, Cyril" uniqKey="Llamoso C" first="Cyril" last="Llamoso">Cyril Llamoso</name><name sortKey="Lovegren, Meghan" sort="Lovegren, Meghan" uniqKey="Lovegren M" first="Meghan" last="Lovegren">Meghan Lovegren</name><name sortKey="Trinh, Huy" sort="Trinh, Huy" uniqKey="Trinh H" first="Huy" last="Trinh">Huy Trinh</name></country><country name="Italie"><noRegion><name sortKey="Carosi, Giampiero" sort="Carosi, Giampiero" uniqKey="Carosi G" first="Giampiero" last="Carosi">Giampiero Carosi</name></noRegion></country><country name="Turquie"><noRegion><name sortKey="Akarca, Ulus S" sort="Akarca, Ulus S" uniqKey="Akarca U" first="Ulus S" last="Akarca">Ulus S. Akarca</name></noRegion></country><country name="Argentine"><noRegion><name sortKey="Gadano, Adrian" sort="Gadano, Adrian" uniqKey="Gadano A" first="Adrian" last="Gadano">Adrian Gadano</name></noRegion></country><country name="France"><region name="Grand Est"><name sortKey="Habersetzer, Francois" sort="Habersetzer, Francois" uniqKey="Habersetzer F" first="François" last="Habersetzer">François Habersetzer</name></region></country><country name="Australie"><region name="Victoria (État)"><name sortKey="Sievert, William" sort="Sievert, William" uniqKey="Sievert W" first="William" last="Sievert">William Sievert</name></region></country><country name="Canada"><noRegion><name sortKey="Wong, David" sort="Wong, David" uniqKey="Wong D" first="David" last="Wong">David Wong</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005402 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005402 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22643350
|texte= Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22643350" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |